Cox Capital Mgt LLC Trims Stock Position in Abbott Laboratories $ABT

Cox Capital Mgt LLC trimmed its stake in Abbott Laboratories (NYSE:ABT) by 23.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,827 shares of the healthcare product maker’s stock after selling 8,631 shares during the period. Abbott Laboratories makes up 2.2% of Cox Capital Mgt LLC’s investment portfolio, making the stock its 17th largest holding. Cox Capital Mgt LLC’s holdings in Abbott Laboratories were worth $3,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sky Investment Group LLC lifted its position in Abbott Laboratories by 0.3% in the fourth quarter. Sky Investment Group LLC now owns 102,881 shares of the healthcare product maker’s stock valued at $12,890,000 after acquiring an additional 285 shares during the last quarter. Spire Wealth Management increased its position in shares of Abbott Laboratories by 1.4% during the fourth quarter. Spire Wealth Management now owns 6,541 shares of the healthcare product maker’s stock worth $820,000 after purchasing an additional 92 shares in the last quarter. Baron Wealth Management LLC lifted its holdings in shares of Abbott Laboratories by 13.0% in the 4th quarter. Baron Wealth Management LLC now owns 5,735 shares of the healthcare product maker’s stock valued at $719,000 after purchasing an additional 662 shares during the last quarter. Chesley Taft & Associates LLC boosted its position in shares of Abbott Laboratories by 8.3% in the 4th quarter. Chesley Taft & Associates LLC now owns 241,771 shares of the healthcare product maker’s stock valued at $30,291,000 after purchasing an additional 18,609 shares during the period. Finally, Cypress Wealth Services LLC boosted its position in shares of Abbott Laboratories by 24.9% in the 4th quarter. Cypress Wealth Services LLC now owns 2,955 shares of the healthcare product maker’s stock valued at $370,000 after purchasing an additional 589 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $30,397.54. Following the transaction, the executive vice president directly owned 38,573 shares of the company’s stock, valued at $4,458,267.34. This represents a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ABT. Citigroup cut their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Evercore lowered their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. The Goldman Sachs Group reduced their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Oppenheimer decreased their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, Leerink Partners dropped their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Trading Down 0.4%

Shares of ABT stock opened at $104.12 on Friday. The company has a market capitalization of $181.35 billion, a P/E ratio of 27.99, a price-to-earnings-growth ratio of 1.65 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $110.82 and its two-hundred day moving average is $122.06. Abbott Laboratories has a twelve month low of $102.41 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the prior year, the business earned $1.34 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.